Halozyme Therapeutics (HALO)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Halozyme Therapeutics (HALO)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Key Insights
Critical company metrics and information
Share Price
$48.40Market Cap
$6.16 BillionTotal Outstanding Shares
127.23 Million SharesTotal Employees
373Dividend
No dividendIPO Date
March 12, 2004SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.halozyme.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-300.49 Million |
| Net Cash Flow From Operating Activities | $402.95 Million |
| Net Cash Flow From Investing Activities | $-300.49 Million |
| Net Cash Flow From Financing Activities | $-222.37 Million |
| Net Cash Flow From Financing Activities, Continuing | $-222.37 Million |
| Net Cash Flow | $-119.91 Million |
| Net Cash Flow From Operating Activities, Continuing | $402.95 Million |
| Net Cash Flow, Continuing | $-119.91 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Revenues | $947.36 Million |
| Basic Average Shares | $379.94 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Cost Of Revenue | $169.66 Million |
| Income Tax Expense/Benefit | $87.63 Million |
| Net Income/Loss Attributable To Parent | $392.47 Million |
| Net Income/Loss | $392.47 Million |
| Other Operating Expenses | $71.05 Million |
| Basic Earnings Per Share | $3.07 |
| Diluted Earnings Per Share | $3.02 |
| Research and Development | $79.94 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Diluted Average Shares | $258.19 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Benefits Costs and Expenses | $467.26 Million |
| Gross Profit | $777.70 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $392.47 Million |
| Selling, General, and Administrative Expenses | $149.69 Million |
| Operating Income/Loss | $477.01 Million |
| Income/Loss From Continuing Operations Before Tax | $480.09 Million |
| Costs And Expenses | $470.35 Million |
| Income/Loss From Continuing Operations After Tax | $392.47 Million |
| Operating Expenses | $300.69 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $2.12 Billion |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Liabilities | $1.67 Billion |
| Equity | $452.70 Million |
| Other Current Assets | $964.51 Million |
| Long-term Debt | $1.50 Billion |
| Fixed Assets | $39.98 Million |
| Noncurrent Liabilities | $1.56 Billion |
| Other Current Liabilities | $96.42 Million |
| Other Non-current Liabilities | $52.36 Million |
| Assets | $2.12 Billion |
| Prepaid Expenses | $31.05 Million |
| Equity Attributable To Parent | $452.70 Million |
| Inventory | $131.41 Million |
| Accounts Payable | $12.40 Million |
| Current Assets | $1.13 Billion |
| Intangible Assets | $419.59 Million |
| Current Liabilities | $108.81 Million |
| Noncurrent Assets | $991.05 Million |
| Other Non-current Assets | $531.49 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.